Aktis Oncology, Inc. (AKTS) has a negative trailing P/E of -32.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -3.07%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2022 | -43.6 | 0.00 | -40.61 | 0.00 | - |
| 2023 | -27.3 | -0.45 | -16.87 | 0.00 | - |
| 2024 | -17.8 | -0.33 | -8.89 | 525.20 | - |
| 2025 | -18.5 | 0.55 | -8.05 | 181.08 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.54 | $16.96K | $-9.11M | -53691.6% |
| 2018 | $-1.04 | $1.21M | $-21.74M | -1799.8% |
| 2019 | $-1.12 | $1.44M | $-30.88M | -2139.9% |
| 2020 | $-1.21 | $1.79M | $-40.87M | -2283.1% |
| 2021 | $-1.08 | $6.62M | $-46.92M | -708.9% |
| 2022 | $-1.10 | $15.35M | $-59.19M | -385.6% |
| 2023 | $-1.00 | $27.12M | $-63.56M | -234.3% |
| 2024 | $-1.89 | $27.38M | $-167.95M | -613.3% |
| 2024 | $0.00 | $1.49M | $-43.98M | -2957.6% |
| 2025 | $0.00 | $6.5M | $-63.73M | -980.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.20 | $-0.21 – $-0.19 | $62.4M | $56.73M – $68.06M | 1 |
| 2026 | $-1.39 | $-1.72 – $-0.77 | $12.93M | $7M – $21.8M | 3 |
| 2027 | $-1.81 | $-2.65 – $-1.05 | $20.1M | $7M – $35M | 3 |
| 2028 | $0.00 | $0.00 – $0.00 | $15.4M | $6.53M – $26.48M | 1 |
| 2029 | $-4.20 | $-8.13 – $-1.05 | $20.53M | $8.7M – $35.31M | 1 |
